AstraZeneca's Imfinzi gets FDA priority review for biliary tract cancer

May 05, 2022 6:08 AM ETAstraZeneca PLC (AZN)By: Ravikash, SA News Editor

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration granted priority review to AstraZeneca's (NASDAQ:AZN) Imfinzi, in combination with standard-of-care chemotherapy, to treat patients with locally advanced or metastatic biliary tract cancer (BCT).
  • The British pharma giant

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.